Related Experiment Videos
[Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)]
Abstract:
Cefotaxime was given to 26 patients with serious infections resistant to other antibiotics. 15 patients were suffering from septicaemia due to Gram-negative bacilli, which were caused either by a single organism (13 cases:" of which Serratia in 6, Klebsiella in 3) or by several organisms (2 cases); 7 had upper urinary tract infections (caused by Serratia in 4 patients), and 6 had miscellaneous infections (two of these were purulent post-operative meningitis). The pathogens were usually resistant to ampicillin and cephalothin. Cefotaxime was administered at a daily dose of 3 g in 22 patients, irrespective of the renal function, and of 6 g in 4 patients (2 meningitis). Treatment included an aminoglycoside in 12 cases. The efficacy of cefotaxime was very satisfactory in 23 of the 26 patients.
Insights
Cefotaxime demonstrated high efficacy in treating serious infections caused by antibiotic-resistant Gram-negative bacteria. This cephalosporin antibiotic proved very satisfactory in 23 out of 26 patients with severe conditions like septicaemia and meningitis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Context:
- Serious infections pose a significant challenge, particularly when caused by multidrug-resistant Gram-negative bacilli.
- Conventional antibiotics like ampicillin and cephalothin often show limited efficacy against these resistant pathogens.
- Cefotaxime, a third-generation cephalosporin, offers a potential therapeutic option for severe bacterial infections.
Purpose:
- To evaluate the clinical efficacy and safety of cefotaxime in patients with serious infections.
- To assess cefotaxime's effectiveness against Gram-negative bacterial infections, including septicaemia, urinary tract infections, and meningitis.
- To determine the optimal dosage and treatment regimens for cefotaxime in critically ill patients.
Summary:
- Twenty-six patients with serious infections, predominantly Gram-negative bacterial septicaemia and urinary tract infections, were treated with cefotaxime.
- Pathogens involved were frequently resistant to ampicillin and cephalothin.
- Cefotaxime was administered at daily doses of 3g or 6g, with 12 patients also receiving an aminoglycoside.
- The treatment yielded very satisfactory results in 23 out of 26 patients, indicating high efficacy.
Impact:
- Cefotaxime represents a valuable therapeutic option for managing severe infections caused by multidrug-resistant Gram-negative bacteria.
- The study supports the use of cefotaxime in clinical practice for infections where other antibiotics have failed.
- Further research may explore combination therapies and specific dosing strategies to optimize cefotaxime's impact on patient outcomes.